Chindex Medical Acquires 10 ViewRay MRIdian® Systems for Advanced Cancer Treatment
ViewRay, Inc. (NASDAQ: VRAY) has announced that Chindex Medical Limited, a subsidiary of Fosun Pharma, has ordered 10 MRIdian MR-Guided Therapy Systems to enhance cancer treatment options in China. The MRIdian system, approved by China's NMPA in September 2022, allows for precise radiation therapy, significantly improving patient care. Over 27,000 patients have benefited from MRIdian's advanced technology, which minimizes radiation exposure to healthy tissue. This partnership deepens collaboration with Fosun Pharma, aiming to address the rising cancer burden in China.
- Chindex Medical's order of 10 MRIdian systems boosts ViewRay's market presence in China.
- Regulatory approval of MRIdian allows access to a large patient population in China.
- Over 27,000 patients treated with MRIdian underscores its established efficacy and potential market demand.
- None.
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
DENVER, Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Chindex Medical Limited (Chindex), through its subsidiary, has ordered 10 MRIdian® MR-Guided Therapy Systems. Chindex, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), has been ViewRay's distribution partner since 2019. MRIdian received regulatory approval in September 2022 from the National Medical Products Administration (NMPA), allowing for its sale and utilization throughout China. This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option, MRIdian Stereotactic MRI-Guided Adaptive Radiotherapy (SMART).
"The integration of a ground-breaking radiation therapy system that's guided by MRI is key to remaining at the forefront of personalized cancer care," said Marie Li, CEO of Chindex. "MRIdian will allow physicians to offer a leading-edge, state-of-the-art technology to address the increasing burden of cancer prevalence in China."
"We are excited to deepen our Fosun Pharma relations by announcing this level of commitment from our partners at Chindex," said Scott Drake, the president and CEO of ViewRay. "Chindex is focused on driving innovation and challenging the status quo of radiation oncology in China, bringing MRIdian's advanced technology to a deserving patient population."
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs at risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for the delivery of the prescribed dose to the target while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.
To date, over 27,000 patients have been treated with MRIdian. Currently, 56 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. For a list of treatment centers, please visit: https://viewray.com/mridian-treatment-centers/
Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.
The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary, or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration. Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
Chindex Medical Limited (CML) is a leading provider of medical equipment. With over 1500 employees worldwide and headquarters located in China, the Company's strategy is to leverage its cross-cultural expertise to provide leading-edge healthcare technologies and quality products to healthcare markets globally. Further Company information may be found at the Company's website at http://www.chindexmedical.com.
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc. ViewRay is a medical device manufacturer and cannot and does not recommend specific treatment approaches. Individual results may vary. The results described herein may not be predictive.
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, ViewRay's financial guidance for the full year 2022, anticipated future orders, anticipated future operating and financial performance, treatment results, therapy adoption, innovation, and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the COVID-19 pandemic, including its impacts across our businesses on demand, our operations and global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
View original content:https://www.prnewswire.com/news-releases/chindex-medical-acquires-10-viewray-mridian-systems-for-advanced-cancer-treatment-301714633.html
SOURCE ViewRay, Inc.
FAQ
What is the significance of Chindex Medical's order of 10 MRIdian systems?
When was MRIdian approved for use in China?
How does the MRIdian system improve cancer treatment?
What is the expected impact of the order on ViewRay's operations?
